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Abstract
Background: Despite the use of hepatitis B (HB) vaccine and hepatitis B immunoglobulin (HBIG), a portion of infants are still
non- or low-responders, or even immunoprophylaxis failure. We aimed to determine the immune response in the infants
from the mothers being positive for hepatitis B surface antigen (HBsAg), by which the infants received three doses of HB
vaccine in combination with two-dose 200 IU HBIG injections.
Methods: In this retrospective study, 621 infants from HBsAg-positive mothers in Beijing YouAn Hospital between January
2008 and December 2009 were included. All the infants were given three doses of 10 mg HB vaccine (at 0, 1 and 6 months of
age) and two-dose of 200 IU HBIG (at birth and in 2 weeks of age). Serum HBsAg and antibody to HBsAg (anti-HBs) in all the
infants were determined at 7 months of age.
Results: Of the 621 infants, 2.9% were immunoprophylaxis failure (positive for HBsAg), 1.4% were non-responders (anti-HBs
undetectable), 95.7% were responders. The 594 responders could be categorized into three subsets, 22 were 10 to 99 IU/L
for anti-HBs levels, 191 were 100 to 999 IU/L, and 381 were $1000 IU/L. The immunoprophylaxis failure rate was at 0% and
5.2% for the infants of HBeAg-negative and HBeAg-positive mothers(P,0.001). Infants from mothers with detectable HBV
DNA had higher incidence of immunoprophylaxis failure than those of mothers without detectable HBV DNA (P=0.002).
The factors including gender, birth weight, gestation weeks, the rates of maternal HBeAg-positive, and detectable HBV DNA
did not contribute to the no response to HB vaccination.
Conclusions: Through vaccination by three doses of HB and two-dose of HBIG, majority of the infants (95.7%) achieved a
protective level of anti-HBs at 7 months of age. Maternal HBeAg-positive and HBV DNA detectable were associated with the
immunoprophylaxis failure, but not contribute to the non- or low-response to HB vaccination.
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Introduction
Chronic HBV infection is still prevalent worldwide, and it is a
major cause of liver-related morbidity and mortality [1–3]. About
15–25% of the HBV infected patients could eventually develop
cirrhosis, liver failure, or hepatocelluar carcinoma, (HCC) later in
their life.
Passive and active immunizations are the most effective
measures to prevent HBV infection and its consequences. For
the babies from HBsAg positive mothers, use of HB vaccine and
HBIG after 12 hour of birth tremendously reduces the HBV
infection rate [4–6]. However, despite the administration, the
incidence of non-responders or low-responders, even immunopro-
phylaxis failure still remains [7–10].
Previous studies have demonstrated that combination of both
passive and active vaccination by HB and HBIG is superior
significantly to the sole vaccination with either HB or HHIG to
reduce hepatitis B occurrence [7,11]. However, in most of the
previous studies, only one dose of HBIG was used. To date, the
large scale study to evaluate the immune effect of two-dose HBIG
plus three doses of recombinant HB vaccine in infants of HBsAg-
positive mothers has not been described Therefore, the aim of
this study was to investigate the immune response and protective
efficacy by a combination of two-dose HBIG and three doses of
recombinant HepB vaccine for infants of HBsAg-positive
mothers.
Methods
Study Population
In this retrospective study, newborn infants of HBsAg positive
mothers were included, and all the mothers were consecutively
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Beijing YouAn Hospital, Capital Medical University, from
January 2008 to December 2009. Complete medical records were
analyzed for mothers and infants. All mothers were confirmed as
chronic HBV infectants.
Mothers with one of the following situations were excluded: 1)
were given anti-viral, or immune-modifying therapy during
pregnancy; 2) co-viral infection; 3) any immunologically compro-
mised conditions. Infants exclusion criteria were as follows: 1) with
low birth weight; 2) with premature birth; 3) incompletion of
passive-active HB immunoprophylaxis; 4) HBsAg were not tested
at 7 months of age or lost of follow-up. In the total 1,157 potential
infant participants, 536 were excluded due to the various reasons
mentioned above, and therefore 621 infants were included in the
final analysis. The flow chart of the participants enrolled in the
study was summarized in Figure 1.
This study was approved by the Institutional Review Board
(IRB) of Beijing YouAn Hospital, Capital Medical University. The
informed consent was waived by the IRB because this study was a
retrospective assessment.
Immunization Schedule
All infants received two doses (at birth and 2 weeks of age) of
HBIG (Chengdu Institute of Biological Products, China; Hualan
Biological Engineering Inc., China) injection, 200 IU (1.0 ml)
each and three doses (in 0, 1, and 6 months schedule)10 mg
(0.5 ml) of recombinant HB vaccine (hansenula yeast vaccine,
Dalian Hissen Bio-pharm Co., China). The first HBIG and HB
vaccine were given within 6 hours of birth.
The infants were consecutively followed-up in the Department
of Obstetrics and Gynecology in Beijing YouAn Hospital, Capital
Medical University, from August 2008 to June 2010. The serum
HBV-markers (HBsAg, anti-HBs, HBeAg, anti-HBe and anti-
HBc) of all infants were measured at 7 months of life.
Laboratory Examination
In 65.5% (407/621) of mothers, the HBV markers were
detected using chemiluminescent microparticle immunoassay
(CMIA) kits (Abbott Diagnostics, USA), in 25.1% (156/621) of
mothers, HBV markers were detected using electrical chemilumi-
nence immunoassay kits (Roche Laboratories, Germany), and
9.3% (58/621) mothers by enzyme-linked immunosorbent assay
(ELISA) kits (Beijing Wantai Biological Pharmacy Enterprise Co.,
China) at the central laboratory of Beijing YouAn Hospital,
Capital Medical University. All the infants’ HBV markers were
measured by CMIA kits at the central laboratory of Beijing Youan
Hospital, Capital Medical University.
The serum HBV DNA levels in pregnant women were tested by
real-time quantitative Polymerase Chain Reaction (PCR) kit
(Shanghai Kehua Bio-engineering Co., Ltd., China) at Beijing
YouAn Hospital, Capital Medical University (the detection of
HBV DNA ranged 500–10
8 copies/ml).
Outcome Assessment
Infants positive for HBsAg were considered immunoprophylaxis
failure and HBV infection. The non-responder, low-responder,
medium-responder and high-responder were defined as the infant
negativeforHBsAgoranti-HBs,10 IU/L,anti-HBs10–100 IU/L,
anti-HBs 100–1,000 IU/L, and anti-HBs$1 000 IU/L, respec-
tively. The factors for immunoprophylaxis failure, the associa-
tion between non- or low-response to the HB vaccination were
also analyzed. Adverse events (AEs) or severe AEs were
recorded.
Statistical analysis
The database was established with EpiData 3.02. An indepen-
dent double input method was used to ensure the quality of data.
Characteristics of the infants in immunoprophylaxis failure group
and non-failure group, infants with non-responder and responder
were compared using Student’s test for continuous variables and
Chi-square or Fisher’s exact tests for categorical variables. The
one-way ANOVA test or the chi-square for R6C tables test was
used for more than two groups, Mann-Whitney U test was used for
the frequency distribution of different responders between
different groups. The data were analyzed by using Statistical
Package for Social Science (SPSS) for windows, Version 13.0
(SPSS Inc., Chicago, IL, USA). All tests were two-tailed with the
risk set at 5%, and statistically significance was defined as P,0.05.
Figure 1. Flow chart of the participants enrolled in the study. A total of 1157 infants of HBsAg-positive mothers from January 2008 to
December 2009 in Beijing Youan Hospital were reviewed. Of the 1157 infants, 536 were excluded. Thus, 621 infants were included and analyzed in the
study.
doi:10.1371/journal.pone.0026748.g001
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Characteristics of Infants
A total of 621 infants were included in this study. Among them,
347 (55.9%) were born to mothers positive for both HBsAg and
HBeAg, 409 (65.9%) were born to mothers with detectable HBV
DNA. The demographics and baseline characteristics of the
infants are shown in Table 1.
The Immunization Outcome in the Infants
Of the 621 infants, 18 were HBsAg-positive and anti-HBs
negative (immunoprophylaxis failure) at 7 months. The rate of
HBV infection was 2.9% (18/621), all the immunoprophylaxis
failure infants were born to mothers positive for both HBsAg and
HBeAg. Nine infants (1.4%, 9/621) did not achieve a protective
level (#10 IU/L) of anti-HBs despite the use of three doses of HB
vaccine and became non-responders. A total of 594 (95.7%)
infants achieved anti-HBs$10 IU/L and became responders. Of
these 594 responders, 22 were low responders (anti-HBs 10 to
99 IU/L), 191 weremedium responders (anti-HBs 100 to 999 IU/L)
and 381 were high responders (anti-HBs$1000 IU/L).
Factors Associated with Immunoprophylaxis Failure
HBV infection by mother-to-child transmission (HBV immu-
noprophylaxis failure) occurred in 18 of the total 621 infants
(2.9%), the other 603 infants were non-failure infants. In Table 2,
possible factors related to immunoprophylaxis failure were
analyzed. The results showed that maternal HBeAg-positive and
mother with detectable HBV DNA were strongly associated with
infant’s immunoprophylaxis failure (P,0.001 and P=0.002,
respectively). Other factors such as ALT level before delivery,
birth weight and gestation weeks were not significantly related to
the failure of immunoprophylaxis.
Characteristics of non-Responders
Of the 603 non-immunoprophylaxis-failure infants, nine infants
became non-responders after the combined HB vaccination and
HBIG injection, while 594 infants achieved protective level (anti-
HBs$10 IU/L) designated as responders. The demographic data,
maternal data and perinatal data between the non-responders and
responders were compared. The results showed that the maternal
ALT before delivery, gestation weeks, birth weight and other
factors were not associated with non-response to HB vaccination
(Table 3).
Vaccination Responders and Their Maternal HBV
Infection Status
We further divided the 603 infants who were non immunopro-
phylaxis failure into the following groups, 1) infants of HBeAg
positive mothers, and 2) infants of HBeAg negative mothers; or 3)
infants of detectable HBV DNA mothers, and 4) infants of
undetectable HBV DNA mothers. Distributions of responders
groups are shown in Figure 2 and Figure 3. Results indicated that
the distribution of responders did not significantly differ between
the maternal HBeAg positive group and maternal HBeAg negative
group (P=0.631), and between the mothers with detectable HBV
DNA and without detectable HBV DNA (P=0.912).
Safety
Among the 621 infants, adverse events (AEs) were reported in
five infants (0.8%). Two infants (0.3%) had injection side (right
upper arm) reaction to the first dose vaccine, two infants (0.3%)
developed fever, and one infant (0.2%) reported hives. There were
no severe AEs attributable to vaccination.
Discussion
To the best of our knowledge, this is the first report, showing a
regimen of three doses of 10 mg HB recombinant vaccine plus two-
dose of 200 IU HBIG, and with a 7-month follow-up for infants of
HBsAg positive mothers. Our results showed most infants (95.7%)
achieved protective level of antibodies (anti-HBs$10 IU/L) at 7
months of age after receiving three doses HB vaccine and two-dose
of HBIG.
In drastic contrast to placebo as control or non-intervention,
administration of HBIG alone or vaccination alone significantly
reduced hepatitis B occurrence [7]. In a report by Beasley et al.,
172 infants of HBeAg positive HBsAg carrier mothers were given
HBIG plus HBV vaccine and were followed for up to 2 years
after birth. Overall, there was a significant difference in persistent
HBsAg positivity in 6% (9/156) infants who were immunopro-
phylaxis failure, compared to 88% in historical controls [12].
Moreover, several previous studies showed the similar results:
compared with sole HB vaccination or sole HBIG, combination
of HB vaccine and HBIG significantly decreased the risk of
perinatal transmission of HBV [7]. Therefore, the Centers for
Disease Control and Prevention (CDC) in the US and the
Advisory Committee on Immunization Practices (ACIP) both
recommended administering immunoprophylaxis of HB vaccine
and HBIg to those infants [13]. Similarly, the Chinese Society of
Hepatology and Chinese Society of Infectious Diseases, and
Chinese Medical Association also recommended the use of HB
vaccine combined with HBIg for the infants of HBsAg positive
mothers [14,15].
Several previous studies had evaluated the immune outcomes of
HB vaccine plus different doses of HBIG vaccination schedules in
preventing perinatal transmission of HBV [11,12]. In a double-
blind randomized placebo-controlled study, Wong et al. compared
Table 1. Baseline characteristics of the infants.
Characteristics No. (%) of infants (Total infants 621)
Sex
Female 289 (46.6)
Male 332 (53.4)
Gestation weeks
37–38 33 (5.3)
38–39 108 (17.4)
39–40 215 (34.6)
40–41 186 (30.0)
41–42 74 (11.9)
$42 5 (0.8)
Birth weight (g)
2500–3000 89 (14.3)
3000–3500 286 (46.1)
3500–4000 197 (31.7)
$4000 49 (7.9)
Singleton
Yes 615 (99.0)
No 6 (1.0)
Abbreviations: HBV, hepatitis B virus.
doi:10.1371/journal.pone.0026748.t001
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mothers, and found the persistence of HBsAg in infants was
significantly lower in the three immunoprophylaxis groups (2.9%
in receiving HB vaccine plus seven monthly HBIG injections
group, 6.8% in vaccination plus one-dose HBIG injection group
and 21.0% in HB vaccine alone group), compared with placebo
control group (73.2%, P,0.0001). Moreover, the authors reported
that vaccination alone was significantly less protective than
vaccination plus multiple HBIg injections [11]. In a randomized
double-blind, placebo-controlled efficacy trial of HBIG for
prevention of the mother-to-infant transmitted HBsAg carrier
state by Beasley et al. [16], HBIG was given immediately after
birth to infants of e antigen positive HBsAg carrier mothers, and
all infants were followed for at least 15 months. Among 61 placebo
recipients, the carrier rate was 92%; compared with 26% among
57 infants who received 0.5 ml HBIG at birth, 3 months, and 6
months, and 54% among 67 infants who received a single 1.0 ml
dose of HBIG at birth only. Efficacy was 71 and 42%, respectively,
for the two treatment schedules. In a study by Grosheide et al.
[17], for the infants born to HBsAg positive carrier mothers, an
additional dose of 1 ml HBIG at 3 month of age did not increase
the effect on prevention HBV transmission. However, transmis-
sion of HBV from one HBV infection mother to her infant is
thought to occur generally the perinatal period, and the additional
HBIG passive immunization should be given with one month after
birth. Therefore, the multiple HBIG injections will not show
significant additional benefit in preventing HBV perinatal
transmission for the infants by mothers with HBsAg-positive when
were given after one month of age.
Our results showed that immunoprophylaxis failure occurred in
2.9% (18/621) infants despite of receiving two-dose of HBIG
combined with three doses HBV vaccination after birth. This
immunoprophylaxis failure occurred more likely in infants of
mothers positive for HBeAg and with detectable HBV DNA.
These results are consistent with the previous reports [10,18–21],
indicating that the maternal HBV DNA and HBeAg positivity are
the most important factors for the failure of immunoprophylaxis in
infants of HBsAg seropositive mothers.
Table 2. Factors correlated with immunoprophylaxis failure.
Variables Failure (n=18) Non-failure (n=603) P value
Demographic data
Sex (F:M) 5:13 284:319 0.105
Han nationality 17 (94.4) 569 (94.4) 1.000
Maternal Data
Age at delivery (years, mean 6 SD) 27.165.2 27.864.2 0.513
HBeAg positive 18 (100) 329 (54.6) ,0.001
HBV DNA detectable 18 (100) 391 (64.8) 0.002
ALT before delivery (IU/L, mean 6 SD) 17.268.6 19.8624.4 0.652
Perinatal factors
Gestation weeks (w, mean 6 STD) 39.561.3 39.361.1 0.383
Birth weight (g, mean 6 STD) 32926406 33946422 0.306
1 minute APGAR score 9.361.1 9.460.7 0.451
Abbreviations: HBV, hepatitis B virus; ALT, alanine transaminase; HBeAg, hepatitis B e antigen ; HBsAg, hepatitis B surface antigen.
doi:10.1371/journal.pone.0026748.t002
Table 3. Characteristics correlated with response and non-response n (%).
Variables Non-responders (n=9) Responders (n=594) P value
Demographic data
Sex (F:M) 3:6 281:313 0.619
Han nationality 9 (100.0) 569 (95.8) 1.000
Maternal Data
Age at delivery (years, mean 6 SD) 28.962.5 27.864.2 0.418
HBeAg positive 5 (55.6) 324 (54.5) 1.000
HBV DNA detectable 6 (66.7) 385 (64.8) 1.000
ALT before delivery (IU/L, mean 6 SD) 24.2615.5 19.8624.5 0.589
Perinatal factors
Gestation weeks (w, mean 6 STD) 38.961.5 39.361.1 0.275
Birth weight (g, mean 6 STD) 32836451 33966421 0.306
1 minute APGAR score 9.660.5 9.560.7 0.428
Abbreviations: HBV, hepatitis B virus; ALT, alanine transaminase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen.
doi:10.1371/journal.pone.0026748.t003
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study is lower than that of previous reported, which were usually in
the range of 5% to 15% [8–10,19]. In a study in South Korea
[10], 144 children who born to HBsAg positive mothers (81
mothers were HBeAg-seropositive and 64 mothers with detectable
HBV DNA) received 100 IU HBIG and 10 mcg of plasma-
derived HB vaccine or recombinant HB vaccine with 24 hours
after birth followed by two further administrations of HB vaccine,
and 17 (11.8%) children experienced immunoprophylaxis failure
(HBV infection) after the completion of the HBV vaccination. The
characteristics of the study pregnant women and the infants in this
study were not different from the South Korea study, which
concluded that maternal HBeAg and HBV DNA loadings are the
risk factors for immunoprophylaxis failure.
In the majority of infants of HBsAg-positive mothers,
immunization with vaccination can acquire protective levels of
anti-HBs [7,19]. However, there are still a few infants become
non/low-responders. Previous studies showed the non/low-
responders occurred in about 5–10% healthy individuals
[22,23]. In the current study, 1.4% (9/621) infants showed no
response and 3.5% (22/621) infants were low-responders.
The mechanism of non-response to HBV immunization is
unknown. The vaccine brand, age, male gender, obesity, and
smoking in adult healthy people might be the associated factors
[24,25]. The study by Yen et al showed that male gender, age of
older than 40 years and anti-HBc positive, were associated with
non-response to HB vaccination [26]. Host genetic factors were
also associated with non/low-response to HB immunization
[27,28]. In a study by Liu et al, non-response to HB vaccination
in healthy individuals was associated with HLA B54 in Chinese
[29]. Hsu et al reported the non/low-responses were associated
with over-expression of HLA-DR14-DR52 in Taiwan [30]. In this
study, all the participants were infants, and were given the same
brand of HB vaccine, so the age, smoking and vaccine brands were
Figure 2. Distribution of different responders in mothers with different HBeAg status. Abbreviations: HBeAg, hepatitis B e antigen.
doi:10.1371/journal.pone.0026748.g002
Figure 3. Frequency distribution of different responders in mother with different HBV DNA status. Abbreviations: HBV, hepatitis B virus.
doi:10.1371/journal.pone.0026748.g003
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correlated with non-response to HBV immunization in infants,
including delayed administration vaccination, preterm and low
birth weight [19,31–33]. In order to eliminate the influence of
those factors, all infants included in this study had birth weight
$2500 g, gestation $37 weeks, and were given the same HB
vaccine within 6 hours of birth. The titers of anti-HBs will wane
after vaccination during the follow-up [34,35], so all the infants
were tested HBV seromarkers at 7 months of age. Our results
indicated the gender and birth weight were not correlated with
immune response to vaccination.
There were a number of studies evaluating the immune
outcomes of different vaccination schedules, different recombinant
vaccines in infants of HBsAg positive mothers [7,11,19,36,37], but
few studies evaluated whether maternal HBV infection status
would influence the response to HB immunization in those infants.
Our results showed that maternal HBeAg status and serum HBV
DNA levels did not influence the response to HBV immunization
in infants of HBsAg-positive mothers.
HB vaccination is well tolerated, and HB vaccination combined
with HBIG injection is a well established safe regimen to treat
mother to infant transmission. Most adverse events occurred were
mild, while severe adverse events were rare [38,39]. The adverse
events in this study were similar to those of previous reports [38–
41].
This study had a few limitations. First, the data were collected
only from the infants who received the same immunoprophylaxis
in one center and this may have selecting bias which could affect
the quality of the study. Second, the HBV DNA levels in the
infants at 7 months of age were not tested for identifying the HBV
occult infection.
In summary, the present study showed that a vaccination by
three doses HB vaccine plus two-dose of HBIG is effective way to
prevent mother to infant transmission within the first seven
months of birth. Maternal HBeAg positive and detectable HBV
DNA status are associated with immunoprophylaxis failure, but
not associated with non-/low-response to HB vaccination. Our
results are preliminary, and the further study would focus on the
follow-up of these infants until adolescence and evaluating their
long-term immunological status.
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